Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Mar;47(3):415-419.
doi: 10.1111/jcpt.13511. Epub 2021 Aug 31.

Non-hyperammonaemia valproate-induced encephalopathy: A case report

Ling Chen  1 , Zucai Xu  1 , Hao Huang  1
Affiliations
Case Reports

Non-hyperammonaemia valproate-induced encephalopathy: A case report

Ling Chen et al. J Clin Pharm Ther. 2022 Mar.

Abstract

What is known and objective: Valproate sodium is an effective antiepileptic drug (AED). Serious adverse effects of valproate sodium are uncommon. This case report illustrates the existence of non-hyperammonaemia valproate-induced encephalopathy.

Case description: A 47-year-old woman with epilepsy who developed valproate-induced encephalopathy without hyperammonaemia after valproate sodium treatment, and the symptoms completely subsided after withdrawal of valproate sodium.

What is new and conclusion: Early diagnosis and identification of the mechanisms of non-hyperammonaemia valproate-induced encephalopathy are important. Immediate discontinuation of valproate sodium results in rapid resolution of symptoms in these patients.

Keywords: adverse effect; encephalopathy; epilepsy; non-hyperammonaemia; valproate sodium.

PubMed Disclaimer

References

REFERENCES

    1. Shah S, Wang R, Vieux U. Valproate-induced hyperammonemic encephalopathy: a case report. J Med Case Rep. 2020;14(1):19.
    1. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol. 1999;58(1):31-59.
    1. Rakitin A, Kõks S, Reimann E, Prans E, Haldre S. Changes in the peripheral blood gene expression profile induced by 3 months of valproate treatment in patients with newly diagnosed epilepsy. Front Neurol. 2015;6:188.
    1. Farooq O, Zunga PM, Dar MI, et al. Non-Hyperammonemic valproate encephalopathy. Ann Neurosci. 2014;21(2):76-79.
    1. Ichiyama T, Okada K, Lipton J, Matsubara T, Hayashi T, Furukawa S. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res. 2000;857(1-2):246-251.

Publication types